RP.V - RepliCel Life Sciences Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.00 (0.00%)
At close: 2:30PM EST
Stock chart is not supported by your current browser
Previous Close0.45
Bid0.44 x 0
Ask0.45 x 0
Day's Range0.43 - 0.45
52 Week Range0.34 - 1.90
Avg. Volume43,385
Market Cap10.07M
PE Ratio (TTM)N/A
EPS (TTM)-0.49
Earnings DateNov 27, 2015 - Nov 30, 2015
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
  • RepliCel Life Sciences Successfully Closes Financing
    CNW Grouplast month

    RepliCel Life Sciences Successfully Closes Financing

    VANCOUVER, Oct. 19, 2017 /CNW/ - RepliCel Life Sciences Inc. ("RepliCel" or the "Company") (OTCQB:REPCD - News) (TSX.V:RP.V - News) (Frankfurt:P6P2.F - News), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announces that, further to its News Releases of October 10, 2017 and October 12, 2017, it has closed its non-brokered private placement of 2,815,881 common shares (each, a "Share") at a price of $0.41 per Share for gross proceeds of $1,154,511.21 (the "Offering"). "We are pleased to have secured the support of several key shareholders in the closing of a financing on terms which are favourable to the Company as we execute on the third and final major deliverable we had set out for the Company in 2017," stated RepliCel CEO Lee Buckler.

  • We're sorry this is all we were able to find about this topic.